| Drug Name |
Encorafenib |
| Drug ID |
BADD_D02552 |
| Description |
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations [FDA label]. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung [L3344].
On June 27, 2018, the Food and Drug Administration approved encorafenib and [Binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [FDA label]. |
| Indications and Usage |
Used in combination with [Binimetinib] in metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test [L3335]. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01EC03 |
| DrugBank ID |
DB11718
|
| KEGG ID |
D11053
|
| MeSH ID |
C000601108
|
| PubChem ID |
50922675
|
| TTD Drug ID |
D0TK7R
|
| NDC Product Code |
59651-641; 11014-0345; 62009-1913; 54893-0114; 70255-025; 11014-0344 |
| UNII |
8L7891MRB6
|
| Synonyms |
encorafenib | LGX818 | Braftovi |
